SYN - Dosing underway in Synthetic Bio's early-stage SYN-020 study in intestinal alkaline phosphatase

Synthetic Biologics (SYN) has commenced enrollment and six study participants were dosed in a Phase 1a single-ascending dose clinical trial of SYN-020 intestinal alkaline phosphatase.The Phase 1a study is designed to evaluate safety, tolerability and pharmacokinetics of four single-ascending doses of oral SYN-020 in healthy volunteers.In all, up to 24 healthy adult volunteers will be enrolled into four cohorts, with top-line data expected in Q3.Also, a multiple-ascending dose study of SYN-020 is planned to begin in Q3.SYN-020 is a recombinant bovine IAP formulated for oral delivery to the small intestine.

For further details see:

Dosing underway in Synthetic Bio's early-stage SYN-020 study in intestinal alkaline phosphatase